Two of the world's largest health data providers, IMS Health and SDI, have filed a motion with the US First Circuit Court of Appeals to request a rehearing of the decision to overturn a New Hampshire US District Court ruling that struck down the State's law banning the commercial use of prescriber-identifiable data (Marketletters passim). SDI took over Verispan, one of the original three firms contesting the data-mining restrictions, in July 2008.
In a joint statement, the firms said: "we have reviewed the First Circuit's decision and believe that there is a strong basis for a rehearing. We strongly believe the First Amendment [of the US Constitution] protects the full dissemination of prescriber-identifiable data, which is vital to efforts to improve the quality, efficiency and safety of our health care system. Further, we agree with prior decisions that without these data the potential exists to compromise patient care."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze